TrueHealth

TrueHealth has established itself as a pioneer in China’s percutaneous puncture surgical robot sector, achieving the distinction of developing the nation’s first NMPA-approved soft tissue puncture robot system. Headquartered in the Hengqin-Macao Deep Cooperation Zone, the company combines artificial intelligence with robotic control technology to address critical clinical challenges in tumor diagnosis and minimally invasive treatment.

Company Overview

Founded in March 2018, TrueHealth emerged from collaborative resources spanning Beihang University, Tsinghua University, and the Chinese Academy of Sciences. The company relocated its headquarters from Beijing to Hengqin in 2023, positioning itself within Guangdong’s emerging medical technology corridor and the unique regulatory environment of the Hengqin-Macao cooperation zone.

The company operates as a National High-Tech Enterprise and has earned designation as a National Specialized and Sophisticated “Little Giant” Enterprise. In 2023, TrueHealth was selected for the Hengqin Deep Cooperation Zone’s inaugural cohort of “IPO Reserve Enterprises” and recognized as a 2023 Potential Unicorn Enterprise.

TrueHealth has secured funding from notable investors including CICC Capital, Shenzhen Cooperation Zone Investment, Hengqin Financial Investment, Huajin Capital, and Gree Group’s industrial investment arm. Following completion of its Series B+ round, the company’s valuation reached approximately CNY 1.8 billion.

Core Products

TH-S1 Puncture Surgery Navigation Positioning System

The flagship TH-S1 system became China’s first soft tissue puncture surgical robot to receive NMPA Class III innovative medical device certification in 2022. The system integrates optical navigation, robotic arm positioning, and respiratory tracking into a unified platform for thoracoabdominal puncture procedures.

Clinical data demonstrates over 4,000 completed procedures across nearly 70 major hospitals with a 100% success rate. The system achieves sub-millimeter positioning accuracy and enables “one-shot” targeting of lesions as small as 0.8cm.

TH-P Portable Puncture Navigation System

Approved in December 2024, this compact variant features a lightweight robotic arm design optimized for space-constrained operating environments. The system maintains core navigation and tracking capabilities while offering enhanced portability for diverse clinical settings.

Navigation-Guided Microwave Ablation System

This system received NMPA Class III innovative medical device approval in September 2024, earning recognition as an “International First” from China’s National Medical Products Administration. As the first product to complete the entire development cycle—from project initiation through regulatory approval—within the Hengqin Deep Cooperation Zone, it represents a milestone for the region’s medical device ecosystem.

Technology & Innovation

TrueHealth’s technology platform addresses the primary challenges of percutaneous interventions through four integrated subsystems:

Intelligent Image Analysis: AI-powered lesion identification, anatomical segmentation, and 3D reconstruction of organs, blood vessels, and airways to support surgical path planning.

Optical Navigation: Electromagnetic interference-resistant tracking achieving sub-millimeter positioning accuracy throughout the procedure.

Respiratory Motion Tracking: Real-time monitoring of patient breathing patterns with dynamic lesion tracking to compensate for organ movement during respiration cycles.

Robotic Arm Positioning: Multi-axis mechanical arm system providing stable, precise needle placement across various puncture angles and depths.

The company holds over 300 patent applications with 237 granted, reflecting sustained investment in intellectual property development.

Market Presence

TrueHealth’s products have been deployed in nearly 70 tertiary hospitals across China, with over 130 additional institutions expressing partnership interest. The TH-S1 system supports applications including puncture biopsy, preoperative localization, microwave ablation, and particle implantation across thoracic and abdominal organ procedures.

Both the puncture navigation system and microwave ablation system have been included in Guangdong Province’s inaugural Innovative Drugs and Medical Devices Product Catalog, facilitating accelerated clinical adoption within the province.

Key Milestones

• 2018: Company founded in Beijing
• 2022: TH-S1 receives China’s first NMPA approval for soft tissue puncture robot
• 2023: Headquarters relocated to Hengqin; selected as IPO reserve enterprise; won first prize (CNY 50M) at 3rd Hengqin International Innovation Competition
• 2024 (Sep): Microwave ablation system approved as “International First”
• 2024 (Dec): TH-P portable system approved, bringing total Class III certificates to 5

Frequently Asked Questions

What makes TrueHealth’s puncture robot unique?

TrueHealth developed China’s first NMPA-approved surgical robot specifically designed for soft tissue puncture procedures. The system integrates respiratory motion tracking with optical navigation and robotic positioning—a combination that addresses the unique challenges of targeting moving organs during breathing.

Is TrueHealth publicly traded?

TrueHealth remains privately held as of early 2026. The company has been designated as an IPO reserve enterprise in the Hengqin Deep Cooperation Zone, with management indicating plans to pursue a public listing that would make it the first publicly traded company in the soft tissue puncture robot sector.

What clinical applications does TrueHealth’s technology support?

The company’s systems support percutaneous interventions across multiple organs including lung, liver, and kidney. Specific applications include diagnostic biopsy, preoperative tumor localization, microwave thermal ablation, and radioactive particle implantation for cancer treatment.